How should impaired morning function in rheumatoid arthritis be treated?

Scandinavian Journal of Rheumatology

Volumn 40, Issue SUPPL. 125, 2011, Pages 28-39

  Buttgereit, Frank ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYTOKINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GLUCOCORTICOID; GOLD; HYDROCORTISONE; INFLIXIMAB; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; SALAZOSULFAPYRIDINE;

ARTICLE; BEDTIME DOSAGE; CIRCADIAN RHYTHM; DISEASE DURATION; DOCTOR PATIENT RELATION; DRUG DOSE ESCALATION; DRUG EFFICACY; EXERCISE; HEAT TREATMENT; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MASSAGE; MORNING STIFFNESS; PATHOPHYSIOLOGY; PATIENT COUNSELING; PRESCRIPTION; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TREATMENT RESPONSE; BLOOD; DAILY LIFE ACTIVITY; DELAYED RELEASE FORMULATION; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG ANTAGONISM; PATIENT COMPLIANCE; SECRETION;

ACTIVITIES OF DAILY LIVING; ARTHRITIS, RHEUMATOID; CIRCADIAN RHYTHM; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; GLUCOCORTICOIDS; HUMANS; HYDROCORTISONE; INTERLEUKIN-6; PATIENT COMPLIANCE; PREDNISONE;

EID: 79955637667     PISSN: 03009742     EISSN: 15027732     Source Type: Journal    
DOI: 10.3109/03009742.2011.566438     Document Type: Article

References (78)

1. Khan NA, Yazici Y, Calvo-Alen J, Dadoniene J, Gossec L, Hansen TM, et al. Reevaluation of the role of duration of morning stiffness in the assessment of rheumatoid arthritis activity. J Rheumatol 2009;36:2435-42.
2. Yazici Y, Pincus T, Kautiainen H, Sokka T. Morning stiffness in patients with early rheumatoid arthritis is associated more strongly with functional disability than with joint swelling and erythrocyte sedimentation rate. J Rheumatol 2004;31:1723-6. (Pubitemid 39202511)
3. Kvien TK, Scherer HU, Burmester GR. Rheumatoid arthritis. In: Bijlsma JWJ, editor. EULAR compendium on rheumatic diseases. London: BMJ Publishing Group Ltd, 2009:61-80.
4. Smolen JS, LandewR, Breeveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964-75.
5. Westhoff G, Buttgereit F, Gromnica-Ihle E, Zink A. Morning stiffness and its influence on early retirement in patients with recent onset rheumatoid arthritis. Rheumatology 2008;47:980-4. (Pubitemid 351865919)
6. da Silva JAP, Phillips S, Buttgereit F. Impact of impaired morning function on the lives and well-being of patients with rheumatoid arthritis. Scand J Rheumatol, 2011; 40 Suppl 125:6-11.
7. Tuominen R, Tuominen S, Mottonen T. How much is a reduction in morning stiffness worth to patients with rheumatoid arthritis? Scand J Rheumatol 2011; 40 Suppl 125:12-16.
8. Barton JL. Patient preferences and satisfaction in the treatment of rheumatoid arthritis with biologic therapy. Patient Prefer Adherence 2009;3:335-44.
9. van den Bemt BJ, van den Hoogen FH, Benraad B, Hekster YA, van Riel PL, van Lankveld W. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. J Rheumatol 2009;36:2164-70.
10. de Thurah A, Nrgaard M, Johansen MB, Stengaard-Pedersen K. Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and co-morbidity in a 10-year longitudinal study. Scand J Rheumatol 2010;39:197-205.
11. Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. Value Health 2010;13:805-12.
12. Schwartzman S, Morgan GJ. Does route of administration affect the outcome of TNF antagonist therapy? Arthritis Res Ther 2004;6(Suppl 2):S19-23. (Pubitemid 43666421)
13. Contreras-Ynez I, Ponce De Leon S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. Am J Med Sci 2010;340:282-90.
14. Vliet Vlieland TP. Non-drug care for RA - is the era of evidencebased practice approaching? Rheumatology 2007;46: 1397-404. (Pubitemid 47321578)
15. Vliet Vlieland TP, Pattison D. Non-drug therapies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2009;23: 103-16.
16. Byers PH. Effect of exercise on morning stiffness and mobility in patients with rheumatoid arthritis. Res Nurs Health 1985; 8:275-81.
17. Landewe RB, Peeters R, Verreussel RL, Masek BA, Goei The HS. No difference in effectiveness measured between treatment in a thermal bath and in an exercise bath in patients with rheumatoid arthritis [in Dutch]. Ned Tijdschr Geneeskd 1992;136: 173-6.
18. Hansen TM, Hansen G, Langgaard AM, Rasmussen JO. Longterm physical training in rheumatoid arthritis. A randomized trial with different training programs and blinded observers. Scand J Rheumatol 1993;22:107-12. (Pubitemid 23198112)
19. Sierakowski S, Cutolo M. Morning symptoms in rheumatoid arthritis: a defining characteristic and marker of active disease. Scand J Rheumatol 2011; 40 Suppl 125:1-5.
20. Cutolo M. How should morning function in rheumatoid arthritis be assessed? Bibliographic study of current assessment. Scand J Rheumatol 2011; 40 Suppl 125:17-22.
21. Labitigan M, Sharaf PH, Swearingen C, Yazici Y. Rheumatoid arthritis patients who participated in randomized clinical trials in 1980s versus 2000s: clinical implications of similarities and differences. Ann Rheum Dis 2010;69(Suppl 3):508.
22. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination thearpy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58:220-5. (Pubitemid 29191652)
23. Emery P, Breeveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology 2000;39:655-65. (Pubitemid 30459953)
24. Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, Di Poi E. Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology 2002;41:892-8.
25. Haagsma CJ, van Riel PLCM, de Jong AJL, van de Putte LBA. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind 52 week clinical trial. Br J Rheumatol 1997;36:1082-8.
26. Hamilton J, McInnes IB, Thomson EA, Porter D, Hunter JA, Madhok R, et al. Comparative study of intramuscular gold and methotrexate in a rheumatoid arthritis population from a socially deprived area. Ann Rheum Dis 2001;60:566-72. (Pubitemid 32493982)
27. Rau R, Herborn G, Menninger H, Sangha O. Progression in early erosive rheumatoid arthritis: 12 month results from a randomized controlled trial comparing methotrexate and gold sodium thiomalate. Br J Rheumatol 1998;37:1220-6.
28. Reece RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al. Comparative assessment of lefluonomide and methotrexate for the treatment of rheumatoid arthritis by dynamic enhanced magnetic resonance imaging. Arthritis Rheum 2002; 46:366-72. (Pubitemid 34136573)
29. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of active rheumatoid arthritis with lefluonomide compared with placebo and methotrexate. Arch Intern Med 1999; 159:2542-50
30. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al. Function and health-related quality of life: results from a randomized controlled trial of lefluonomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999;42:1870-8. (Pubitemid 30257751)
31. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Eng J Med 2000; 343:1586-93. (Pubitemid 32162981)
32. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan A-M, Walker D, et al. Effect of the early use of the anti-tumour necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. Arthritis Rheum 2008;59:1467-74.
33. Breeveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumb plus methotrexate versus methotrexate alone or adalimumab alone in patients with early aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37. (Pubitemid 43122183)
34. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz- Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Eng J Med 2004;350:2572-81. (Pubitemid 38758544)
35. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIb randomized, doubleblind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54:1390-400.
36. Emery P, Breeveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372:375-82.
37. Fleischmann R, Vencovsky J, van Vollenhoven R, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis 2009;68:805-11.
38. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50. (Pubitemid 34620189)
39. Genovese MC, McKay JD, Nasonov EL, Mysler EF, da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008; 58:2968-80.
40. Keystone E, van der Heijde D, Mason D, Landewe R, van Vollenhoven R, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 2008;58:3319-29.
41. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor a given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GOFORWARD study. Ann Rheum Dis 2009;68:789-96.
42. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76. (Pubitemid 46768126)
43. Lipsky PE, van der Heijde DMFM, St Clair EW, Furst DE, Breeveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Eng J Med 2000; 343:1594-602. (Pubitemid 32162982)
44. Maini R, St Clair EW, Breeveld F, Furst D, Kalden J, Weisman M, et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999;354:1932-9.
45. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7. (Pubitemid 47309731)
46. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008;67:1096-103.
47. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijtens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis 2009;68:797-804.
48. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97. (Pubitemid 351392039)
49. St Clair EW, van der Heijde D, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized controlled trial. Arthritis Rheum 2004;50:3432-43. (Pubitemid 39488667)
50. Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin M, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. Rheumatology 2006;45:1505-13. (Pubitemid 44817056)
51. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. Ann Rheum Dis 2009;68:1870-7.
52. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Metaanalysis of the efficacy and safety of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy 2010;30:339-53.
53. Kim HY, Lee SK, Song YW, Koh EM, Yoo B, Luo A. A randomized, double-blind, placebo-controlled, phase III study of the human antitumour necrosis factor antibody adalimumab admini- stered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. APLAR J Rheumatol 2007; 10:9-16. (Pubitemid 46390204)
54. Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaulation: the CHANGE study. Mod Rheumatol 2008;18:252-62.
55. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004;50:353-63. (Pubitemid 38198818)
56. Lan JL, Chou SJ, Chen DY, Hsieh TY, Young MJ. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. J Formos Med Assoc 2004;103:618-23.
57. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis: a randomized controlled trial. Ann Intern Med 1999; 130:478-86. (Pubitemid 29135800)
58. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Eng J Med 1999; 340:253-9. (Pubitemid 29063266)
59. Zhang F-C, Hou Y, Huang F, Wu D-H, Bao C-D, Ni L-Q, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a preliminary study from China. APLAR J Rheumatol 2006;9:127-30. (Pubitemid 44057326)
60. Sokka T, Kautiainen H, Pincus T, Toloza S, da Rocha Castelar Pinheiro G, Lazovskis J, et al. Disparities in rheumatoid arthritis disease activity according to gross domestic product in 25 countries in the QUEST-RA database. Ann Rheum Dis 2009; 68:1666-72.
61. Gaikwad M, Belgamwar VS, Tekade A, Gattani S, Surana S. Formulation and evaluation of floating, pulsatile, multiparticulates using pH-dependent swellable polymers. Pharm Dev Technol 2010;15:209-16.
62. Qureshi J, Ahuja A, Baboota S, Chutani K, Jain S, Ali J. Development and evaluation of a time-specific pulsatile-release tablet of aceclofenac: a solution for morning pain in rheumatoid arthritis. Methods Find Exp Clin Pharmacol 2009;31:15-23.
63. Cutolo M, Seriolo B, Craviotto C, Pizzorni C, Sulli A. Circadian rhythms in RA. Ann Rheum Dis 2003;62:593-6. (Pubitemid 36760552)
64. Straub RH, Cutolo M. Circadian rhythms in rheumatoid arthritis: implications for pathophysiology and therapeutic management. Arthritis Rheum 2007;56:399-408.
65. Cutolo M, Masi AT. Circadian rhythms and arthritis. Rheum Dis Clin North Am 2005;31:115-29. (Pubitemid 40082058)
66. Kirwan JR, Clarke L, Hunt LP, Perry MG, Straub RH, Jessop DS. Effect of novel therapeutic glucocorticoids on circadian rhythms of hormones and cytokines in rheumatoid arthritis. Ann N Y Acad Sci 2010;1193:127-33.
67. Meyer-Hermann M, Figge MT, Straub RH. Mathematical modeling of the circadian rhythm of key neuroendocrine-immune system players in rheumatoid arthritis. A systems biology approach. Arthritis Rheum 2009;60:2585-94.
68. Perry MG, Kirwan JR, Jessop DS, Hunt LP. Overnight variations in cortisol, interleukin 6, tumour necrosis factor a and other cytokines in people with rheumatoid arthritis. Ann Rheum Dis 2009;68:63-8.
69. Perry MG, Jessop DS, Hunt LP, Sharif M, Kirwan JR. Overnight variations in IL6 in synovial fluid and plasma in patients with active rheumatoid arthritis. Int J Clin Rheumatol 2010;5:593-600.
70. Cutolo M, Straub RH, Bijlsma JW. Neuroendocrine-immune interactions in synovitis. Nat Clin Pract Rheumatol 2007;3:627-34.
71. Arvidson NG, Gudbjrnsson B, Larsson A, Hllgren R. The timing of glucocorticoid administration in rheumatoid arthritis. Ann Rheum Dis 1997;56:27-31. (Pubitemid 27060569)
72. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 2008;371:205-14.
73. Westhovens R. The importance of chronotherapeutics in the treatment of rheumatoid arthritis. Eur Musculoskeletal Rev 2010;5:9-13.
74. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. Ann Rheum Dis 2010;69:1275-80.
75. Alten R, Doering G, Cutolo M, Gromnica-Ihle E, Witte S, Straub RH, et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with night-time-release prednisone. J Rheumatol 2010;37:2025-31.
76. Buttgereit F, Mehta DP, Kirwan JR, Szechinski J, Boers M, Alten R, et al. Low-dose glucocorticoid chronotherapy of rheumatoid arthritis: 12 week efficacy data of 5 mg modified-release (MR) prednisone. Ann Rheum Dis 2010;69(Suppl 3):220.
77. Buttgereit F, Mehta DP, Kirwan JR, Szechinski J, Boers M, Alten R, et al. Safety data for low-dose glucocorticoid chronotherapy of rheumatoid arthritis with 5 mg modified-release (MR) prednisone in a randomized, double-blind placebo-controlled trial. Ann Rheum Dis 2010;69(Suppl 3):219.
78. Jacobs JW, Bijlsma JW. Modified release prednisone in patients with rheumatoid arthritis. Ann Rheum Dis 2010;69: 1257-9.